| Home | E-Submission | Sitemap | Contact Us |  
REVIEW ARTICLE
J Korean Sleep Res Soc. 2009;6(1):24-28.         doi: https://doi.org/10.13078/jksrs.09006
Treatment of REM Sleep Behavior Disorder
Hye-Jin Moon, and Hyunwoo Nam
Department of Neurology, Boramae Hospital, Seoul National University, Seoul, Korea
Corresponding Author: Hyunwoo Nam ,Tel: +82-2-870-2471, Fax: +82-2-870-3866, Email: hwnam@brm.co.kr
Received: 4 June 2009;  Accepted: 20 June 2009.
Share :  
ABSTRACT
REM sleep behavior disorder (RBD) is clinically characterized by the intermittent loss of normal skeletal muscle atonia during rapid eye movement (REM) sleep with the appearance of elaborate motor activity associated with dream mentation. Clonazepam, a sedating benzodiazepine, is currently regarded as the treatment of choice for RBD. In patients with contraindications to clonazepam, in those unresponsive to clonazepam, or in whom tolerance or serious side effects are observed, a therapeutic trial with melatonin up to 12 mg is recommended. The effect of acetylcholinesterase inhibitors and dopaminergics on RBD symptoms needs future validation. There is no clear evidence of beneficial effect of bilateral subthalamic nucleus stimulation despite the improvement of the sleep architecture.
Keywords: REM sleep behavior disorder | Clonazepam | Melatonin | Pramipexole | Levodopa
Editorial Office
Department of Neurology, Kyungpook National University Chilgok Hospital
807, Hoguk-ro, Buk-gu, Daegu 41404, Republic of Korea
Tel: +82-53-200-2582   Fax: +82-53-200-3299   E-mail: jsleepmed@gmail.com

Copyright© Korean Sleep Research Society. All rights reserved.               powerd by M2community
About |  Browse Articles |  Current Issue |  For Authors and Reviewers